Breaking News, Collaborations & Alliances

ADEL Enters Global License Agreement with Sanofi for ADEL-Y01

ADEL-Y01 is a potential first-in-class antibody therapy for Alzheimer's disease.

Author Image

By: Charlie Sternberg

Associate Editor

ADEL Inc., a biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases, has entered into an exclusive worldwide license agreement with Sanofi, a multinational healthcare company, for the development and commercialization of ADEL-Y01, a potential first-in-class antibody therapy for Alzheimer’s disease, and related backup compounds. ADEL-Y01 is a humanized monoclonal antibody that selectively targets tau protein acetylated at Lysine-280 (acK280). It specif...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters